Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pacibekitug - Tourmaline Bio

Next Previous
Drug Profile

Pacibekitug - Tourmaline Bio

Alternative Names: PAC 001; PF-04236921; PF-4236921; TOUR-006

Latest Information Update: 13 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Tourmaline Bio
  • Class Anti-inflammatories; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Monoclonal antibodies; Urologics; Vascular disorder therapies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cardiovascular disorders; Graves ophthalmopathy; Kidney disorders
  • Preclinical Abdominal aortic aneurysm
  • Discontinued Crohn's disease; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 31 Dec 2025 Novartis intends to file regulatory applications for pacibekitug for the approval of Atherosclerotic Cardiovascular Disease in or after 2029 (Novartis pipeline, December 2025)
  • 04 Dec 2025 Tourmaline Bio completes a phase II TRANQUILITY trial for Kidney disorders in USA (SC) (NCT06362759)
  • 08 Nov 2025 Pharmacodynamics and adverse event data from a phase II TRANQUILITY trial for Kidney disorders presented at American Heart Association Scientific Sessions 2025 (AHA-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top